1st Nov 2010 12:36
For immediate release | 1 November 2010 |
ABCAM PLC
("Abcam" or "the Company")
Result of Annual General Meeting
Abcam plc (AIM: ABC), the rapidly growing bioscience company that markets antibodies via its own online catalogue, announces that at its AGM held earlier today all resolutions put to the meeting were duly passed.
Following approval of the resolution relating to the five for one sub-division of Abcam's ordinary shares of 1 pence each, each ordinary share of 1 pence each in the capital of the Company will be split into five new ordinary shares of 0.2 pence each.
The split is expected to become effective on 15 November 2010. The record date for this change is 12 November 2010.
Abcam | + 44 (0) 1223 696000 |
Jonathan Milner, Chief Executive Officer | |
Jeff Iliffe, Chief Financial Officer | |
Numis Securities | + 44 (0) 20 7260 1000 |
Michael Meade / Nick Westlake, Nominated Adviser | |
James Black, Corporate Broking | |
Buchanan Communications | + 44 (0) 20 7466 5000 |
Mark Court / Jessica Fontaine |
Notes for editors:
About Abcam plc
Abcam is a producer and distributor of research-grade antibodies and related products, headquartered in Cambridge, United Kingdom, with US offices in Cambridge, Massachusetts, and San Francisco, California, and Far East offices in Tokyo and Hong Kong. Abcam was admitted to AIM in November 2005 and trades under the ticker symbol ABC. The Company produces and distributes its own and third-party products to academic and commercial users throughout the world. Product ordering is available through the Company's website www.abcam.com, where customers are also able to access up-to-date and detailed technical product data sheets. All products are sold under the Abcam brand name and the Company's vision is to build the world's largest online resource of high-quality and commercially viable antibodies. Abcam now has an online catalogue of over 66,000 products, most of which are antibodies, from over 250 suppliers and employs 270 staff.
Related Shares:
ABC.L